SEC Form 4 · accession 0001628280-26-060962
Contineum Therapeutics, Inc. · CTNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carmine N. Stengone
Officer — CEO and President · Director
Period of report
Sep 8, 2026
Accepted (ET)
Sep 8, 2026 · 6:08 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001855175
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Sep 8, 2026 | M | 2,500 | $1.01 | A | 19,717 | D | |
| Class A Common StockF2 | Sep 8, 2026 | S | 2,500 | $16.4566 | D | 17,217 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $1.01 | Sep 8, 2026 | M | 2,500 | D | — | Feb 24, 2030 | Class A Common Stock | 2,500 | 274,430 | D |
Explanation of responses
- F1These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.29 to $16.59, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F3Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.